title: Inhibition of cytochrome P450 2C8-mediated drug metabolism by the flavonoid diosmetin.
abstract: The aim of this study was to assess the effects of diosmetin and hesperetin, two flavonoids present in various medicinal products, on CYP2C8 activity of human liver microsomes using paclitaxel oxidation to 6α-hydroxy-paclitaxel as a probe reaction. Diosmetin and hesperetin inhibited 6α-hydroxy-paclitaxel production in a concentration-dependent manner, diosmetin being about 16-fold more potent than hesperetin (mean IC(50) values 4.25 ± 0.02 and 68.5 ± 3.3 µM for diosmetin and hesperetin, respectively). Due to the low inhibitory potency of hesperetin, we characterized the mechanism of diosmetin-induced inhibition only. This flavonoid proved to be a reversible, dead-end, full inhibitor of CYP2C8, its mean inhibition constant (K(i)) being 3.13 ± 0.11 µM. Kinetic analysis showed that diosmetin caused mixed-type inhibition, since it significantly decreased the V(max) (maximum velocity) and increased the K(m) value (substrate concentration yielding 50% of V(max)) of the reaction. The results of kinetic analyses were consistent with those of molecular docking simulation, which showed that the putative binding site of diosmetin coincided with the CYP2C8 substrate binding site. The demonstration that diosmetin inhibits CYP2C8 at concentrations similar to those observed after in vivo administration (in the low micromolar range) is of potential clinical relevance, since it may cause pharmacokinetic interactions with co-administered drugs metabolized by this CYP.
authors.affiliation: Department of Pharmacology and Anaesthesiology, University of Padova, Italy.
authors.forename: Luigi
authors.initials: L
authors.lastname: Quintieri
authors.forename: Pietro
authors.initials: P
authors.lastname: Palatini
authors.forename: Stefano
authors.initials: S
authors.lastname: Moro
authors.forename: Maura
authors.initials: M
authors.lastname: Floreani
mesh_terms: D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D001665:Binding Sites; D065727:Cytochrome P-450 CYP2C8; D005419:Flavonoids / Q000493:pharmacokinetics* / Q000494:pharmacology*; D006569:Hesperidin / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D008658:Inactivation, Metabolic; D008862:Microsomes, Liver / Q000187:drug effects / Q000378:metabolism; D056004:Molecular Dynamics Simulation; D017239:Paclitaxel / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology
chemical_list: D005419:Flavonoids; D006569:Hesperidin; D001189:Aryl Hydrocarbon Hydroxylases; C450259:CYP2C8 protein, human; D065727:Cytochrome P-450 CYP2C8; D017239:Paclitaxel; C013015:hesperetin; C039602:diosmetin